ClinicalTrials.gg
Not yet recruitingNCT07939178Updated Nov 16, 2026

Deep Brain Reorienting (DBR) in Post-traumatic Stress Disorder (PTSD)

An interventional study of Deep Brain Reorienting (DBR) and Treatment-as-usual (TAU) in PTSD and Post-traumatic Stress Disorder (PTSD), sponsored by The Royal Ottawa Mental Health Centre. Not yet recruiting at 1 site in Canada. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by The Royal Ottawa Mental Health Centre · Not applicable, Interventional, and Treatment

Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 126 studies in Stress Disorders, Post-Traumatic with a site in Canada — 33 open to participants now, 41 under way, 2 of them phase 3. Stress Disorders, Post-Traumatic · Canada.

Planned enrollment
86th of 112
20 · median 54
Started
2026
with 15 others
No phase
83 of 126
20 open now
Primary completion
2028-01
later than 27 of 40 live
Registered
126th of 126
by date

Among the 126 studies in Stress Disorders, Post-Traumatic with a site in Canada, this one is the 86th largest by planned enrollment of the 112 interventional ones that give a count, is one of 16 that started in 2026, is one of 83 with no phase, reaches primary completion later than 27 of the 40 other live ones, and was the 126th registered.

Stress Disorders, Post-Traumatic

2,687 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 603 are open to participants now.

Browse Stress Disorders, Post-Traumatic studies →

Open to participants now

33 of the 126 studies in Stress Disorders, Post-Traumatic with a site in Canada are open now. Recruiting first, the newest first:

28 more — sign in →

All 33 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 417 Stress Disorders, Post-Traumatic studies recruiting now, 187 (45%) set no upper age limit and 204 (49%) stop at 75 or younger; 63 take children under 18; 89 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 126 studies in Stress Disorders, Post-Traumatic with a site in Canada, or all of them as a file.
02

Study summary

The goal of this clinical trial is to determine the effects of a clinical treatment called deep brain reorienting (DBR) on post-traumatic stress disorder (PTSD).

We will be investigating if DBR helps reduce PTSD symptoms. To do so, we will be assigning participants to either receive DBR or continue with their current treatment. By comparing the results from the two groups, we will learn if DBR could be an effective treatment for PTSD.

Participants will be randomly assigned (e.g., like the flip of a coin) to receive either eight weekly sessions of DBR treatment or continue with their current treatment. Participants assigned to continue with their current treatment will be offered eight DBR sessions after they have completed the study.

The study will take place online/virtually over video conferencing.

Read the detailed description

This study is a randomized controlled preliminary feasibility trial designed to evaluate the effectiveness of Deep Brain Reorienting (DBR) in reducing PTSD symptoms. DBR was designed by Frank Corrigan, a clinician and scientist interested in the brain mechanisms underlying effective trauma psychotherapy. Study participation will include randomization to either the DBR treatment or treatment-as-usual (TAU) study groups and psychological assessments.

Potential participants will complete an initial screening interview to rule out any obvious exclusions. Individuals that meet preliminary eligibility criteria will be scheduled for an informed consent session. Those who meet criteria for inclusion will be scheduled for a baseline clinical assessment. If appropriate for the study, they will be randomized to one of 2 treatment groups, DBR or TAU. Treatment will entail 8 sessions of DBR, or 8 weeks of TAU (i.e., conventional treatment). After treatment/TAU is complete, a post-treatment assessment interview will take place. Finally, 3 months post-treatment/post-TAU end, a third assessment interview will be completed. For those in the TAU group, 8 sessions of DBR will be offered at this point.

DBR sessions will take place virtually using video conferencing. Short pre/post session questionnaires and ratings will be completed each week to help track the participant's mental state. Bi-weekly pre-session self-report questionnaires will be completed to assess changes in the participant's PTSD symptoms and dissociative experiences. Participants in the TAU group will complete bi-weekly check-ins with a research staff member on weeks 2, 4, 6, and 8 over video conferencing. The check-in sessions are intended to support study retention and ensure that participants have some contact with study staff during their 8-week TAU phase

03

Conditions studied

  • PTSD
  • Post-traumatic Stress Disorder (PTSD)

Keywords

  • Deep Brain Reorienting
  • PTSD
  • Psychotherapy
  • DBR
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18-65 years old;
  • Fluent English speaker;
  • Resident of Ontario, Canada (for psychology licensing purposes);
  • Comfortable using electronic devices (i.e., laptop, tablet, smartphone, etc.);
  • Meet criteria for a primary diagnosis of PTSD via the on the Clinician Administered PTSD Scale (CAPS-5). Given high rates of PTSD co-morbidity with major depressive disorder and anxiety disorders, these participants will not be excluded from the study, allowing for a naturalistic sample;
  • Currently being followed by a family physician or psychiatrist;
  • Able to provide written .

Exclusion criteria

Exclusion Criteria:

Medical

  • History of significant head injury/lengthy loss of consciousness (e.g., a Glasgow Coma Scale Score \< 15 at the time of incident assessed retrospectively by participant);
  • Serious illness (including cardiac, hepatic, renal, respiratory, endocrinologic, neurologic, or hematologic disease) that is not stabilized based on the judgment of primary investigator;
  • Major untreated medical illness (e.g., cancer, thyroid disorder);
  • Any other condition that might interfere with the person's capacity to give , or to adhere to the study protocol.

Psychological/Psychiatric

  • Individuals receiving trauma-based therapy or trauma-focused therapy (e.g., CBT, trauma exposure therapy, EMDR) in the 4 weeks preceding study referral (or from screening to initial assessment interview);
  • Current or past psychotic spectrum disorders, bipolar disorders or psychosis, obsessive-compulsive disorder, schizophrenia will be excluded;
  • Participants will also be excluded for active suicidality, history of pervasive developmental disorders, or any other major medical illnesses;
  • Meeting criteria for substance use disorder in the past three months on the MINI;
  • Chronic opioid analgesic use within the last three months;
  • May not benefit from short-term treatment (e.g., as a result of situational factors, volatile life circumstances), as determined by study assessment
  • Any other condition that might interfere with the person's capacity to give informed consent, or to adhere to the study protocol.

Legal Status

  • Currently involved in trauma-related litigation.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Deep Brain Reorienting (DBR)

    Participants randomly assigned to the DBR group will be asked to attend eight, 50-minute, one-on-one sessions of DBR with a therapist.

    Behavioral: Deep Brain Reorienting (DBR)

  • Active comparator
    Treatment-as-usual (TAU)

    Participants randomly assigned to the TAU group will continue to receive the ongoing conventional treatment that they are currently being provided for 8 weeks (the equivalent time for 8 sessions of DBR in the treatment group).

    Behavioral: Treatment-as-usual (TAU)

Interventions

  • BehavioralDeep Brain Reorienting (DBR)

    DBR involves bringing up a traumatic memory; however, instead of focusing on the emotions or specific events, participants are asked to attend to the muscles in the shoulders, neck, head, and face. These muscles are engaged when attending to stimuli in the environment, including potentially threatening or frightening situations. The DBR therapist guides participants to maintain this focus and provides support to help regulate the central nervous system as needed throughout the session.

  • BehavioralTreatment-as-usual (TAU)

    The TAU condition is intended as a naturalistic usual-care comparison, reflecting the care participants are receiving at the time of enrolment. Participants who are already receiving eligible supportive counselling or other non-trauma-focused therapy may continue that treatment during the 8-week TAU period. Participants who are not receiving treatment at enrolment will not be assigned treatment by the study; for these participants, a period without treatment reflects their usual care at the time of enrolment. TAU treatment is not provided or directed by study therapists. TAU participants will be offered eight sessions of DBR after completing the three-month follow-up assessment interview.

06

What researchers measure

Primary outcomes

  1. Change in clinician-assessed PTSD symptoms from baseline as measured by the Clinician-Administered PTSD Scale-5 (CAPS-5) at the post-treatment assessment.

    The CAPS-5 symptom severity score ranges from 0-80, with higher scores representing greater PTSD symptoms.

    Time frame: From baseline to post-treatment, 8 weeks

  2. Change in clinician-assessed PTSD symptoms from baseline as measured by the Clinician-Administered PTSD Scale-5 (CAPS-5) at the three-month follow-up assessment.

    The CAPS-5 symptom severity score ranges from 0-80, with higher scores representing greater PTSD symptoms.

    Time frame: From baseline to three-month post-treatment follow-up, 5 months

  3. Change in self-reported PTSD symptoms from baseline as measured by the PTSD Checklist for DSM-5 (PCL-5) at the post-treatment assessment.

    The PCL-5 symptom severity score ranges from 0-80, with higher scores representing greater PTSD symptoms.

    Time frame: From baseline to post-treatment, 8 weeks

  4. Change in self-reported PTSD symptoms from baseline as measured by the PTSD Checklist for DSM-5 (PCL-5) at the three-month follow-up assessment.

    The PCL-5 symptom severity score ranges from 0-80, with higher scores representing greater PTSD symptoms.

    Time frame: From baseline to three-month post-treatment follow-up, 5 months

Secondary outcomes

  1. Change in self-reported depressive symptoms from baseline as measured by the Beck Depression Inventory-II (BDI-II) at the post-treatment assessment.

    The BDI-II score ranges from 0-63, with higher scores indicating more severe depression symptoms.

    Time frame: From baseline to post-treatment, 8 weeks

  2. Change in self-reported depressive symptoms from baseline as measured by the Beck Depression Inventory-II (BDI-II) at the three-month follow-up assessment.

    The BDI-II score ranges from 0-63, with higher scores indicating more severe depression symptoms.

    Time frame: From baseline to three-month post-treatment follow-up, 5 months

  3. Change in self-reported dissociative experiences from baseline as measured by the Dissociative Experiences Scale (DES) at the post-treatment assessment.

    The DES score ranges from 0-100, with higher scores indicating greater levels of dissociative experiences.

    Time frame: From baseline to post-treatment, 8 weeks

  4. Change in self-reported dissociative experiences from baseline as measured by the Dissociative Experiences Scale (DES) at the three-month follow-up assessment

    The DES score ranges from 0-100, with higher scores indicating greater levels of dissociative experiences.

    Time frame: From baseline to three-month post-treatment follow-up, 5 months

  5. Change in self-reported physical symptoms from baseline as measured by the Physical Symptoms Scale (PSS) at the post-treatment assessment.

    The PSS score ranges from 0-33, with higher scores indicating more severe physical symptoms.

    Time frame: From baseline to post-treatment, 8 weeks

  6. Change in self-reported physical symptoms from baseline as measured by the Physical Symptoms Scale (PSS) at the three-month follow-up assessment.

    The PSS score ranges from 0-33, with higher scores indicating more severe physical symptoms.

    Time frame: From baseline to three-month post-treatment follow-up, 5 months

  7. Change in self-reported trauma-related shame from baseline as measured by the Trauma-Related Shame Inventory (TRSI) at the post-treatment assessment.

    The TRSI score ranges from 0-72, with higher scores indicating greater levels of trauma-related shame.

    Time frame: From baseline to post-treatment, 8 weeks

  8. Change in self-reported trauma-related shame from baseline as measured by the Trauma-Related Shame Inventory (TRSI) at the three-month follow-up assessment.

    The TRSI score ranges from 0-72, with higher scores indicating greater levels of trauma-related shame.

    Time frame: From baseline to three-month post-treatment follow-up, 5 months

  9. Change in self-reported interoceptive awareness from baseline as measured by the Multidimensional Assessment of Interoceptive Awareness-Version 2 (MAIA-V2) at the post-treatment assessment.

    The MAIA-V2 consists of 37 items comprising eight subscales. Higher scores on the MAIA-V2 subscales indicate greater interoceptive awareness.

    Time frame: From baseline to post-treatment, 8 weeks

  10. Change in self-reported interoceptive awareness from baseline as measured by the Multidimensional Assessment of Interoceptive Awareness-Version 2 (MAIA-V2) at the three-month follow-up assessment.

    The MAIA-V2 consists of 37 items comprising eight subscales. Higher scores on the MAIA-V2 subscales indicate greater interoceptive awareness.

    Time frame: From baseline to three-month post-treatment follow-up, 5 months

07

Study locations

1 site
08

References and documents

Publications

  • Terpou BA, Densmore M, Thome J, Frewen P, McKinnon MC, Lanius RA. The Innate Alarm System and Subliminal Threat Presentation in Posttraumatic Stress Disorder: Neuroimaging of the Midbrain and Cerebellum. Chronic Stress (Thousand Oaks). 2019 Feb 5;3:2470547018821496. doi: 10.1177/2470547018821496. eCollection 2019 Jan-Dec. PubMed 32440590 ↗
  • Lanius RA, Rabellino D, Boyd JE, Harricharan S, Frewen PA, McKinnon MC. The innate alarm system in PTSD: conscious and subconscious processing of threat. Curr Opin Psychol. 2017 Apr;14:109-115. doi: 10.1016/j.copsyc.2016.11.006. Epub 2016 Nov 26. PubMed 28813307 ↗
  • Kearney BE, Corrigan FM, Frewen PA, Nevill S, Harricharan S, Andrews K, Jetly R, McKinnon MC, Lanius RA. A randomized controlled trial of Deep Brain Reorienting: a neuroscientifically guided treatment for post-traumatic stress disorder. Eur J Psychotraumatol. 2023;14(2):2240691. doi: 10.1080/20008066.2023.2240691. PubMed 37581275 ↗
  • Corrigan FM, Christie-Sands J. An innate brainstem self-other system involving orienting, affective responding, and polyvalent relational seeking: Some clinical implications for a "Deep Brain Reorienting" trauma psychotherapy approach. Med Hypotheses. 2020 Mar;136:109502. doi: 10.1016/j.mehy.2019.109502. Epub 2019 Nov 18. PubMed 31794877 ↗
  • Corneil BD, Munoz DP, Chapman BB, Admans T, Cushing SL. Neuromuscular consequences of reflexive covert orienting. Nat Neurosci. 2008 Jan;11(1):13-5. doi: 10.1038/nn2023. Epub 2007 Dec 2. PubMed 18059264 ↗
  • Comoli E, Das Neves Favaro P, Vautrelle N, Leriche M, Overton PG, Redgrave P. Segregated anatomical input to sub-regions of the rodent superior colliculus associated with approach and defense. Front Neuroanat. 2012 Apr 3;6:9. doi: 10.3389/fnana.2012.00009. eCollection 2012. PubMed 22514521 ↗

Individual participant data

Plan to share: No — Individual participant data (IPD) will not be made available to external researchers. De-identified participant data (e.g., questionnaire responses) will only be shared with co-investigators and collaborators at Western University and the University of Alberta to complete analyses for the project. Data sharing agreements will be obtained to share de-identified data between these institutions. Participants will be made aware of this data sharing arrangement during the informed consent process.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Jan 2028, 13 months later.

Of 1,065 non-industry interventional studies with no phase under Stress Disorders, Post-Traumatic, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 53. This study's planned 13 months is below that.

Counting every sponsor, half of 1,093 studies reached it within 34 months; a quarter within 17 and three quarters within 53.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2026
First posted
Nov 16, 2026
StartEst.
Dec 2026
Primary completionEst.
Jan 2028
CompletionEst.
Jul 2028
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07939178
Lead sponsor
The Royal Ottawa Mental Health Centre
Responsible party
Andrew Nicholson (Vice President, Research, Atlas Institute for Veterans and Families, Royal Ottawa Hospital; Associate Professor, University of Ottawa, School of Psychology; Scientist, University of Ottawa Institute of Mental Health Research, The Royal Ottawa Mental Health Centre) — Principal investigator
First posted
Nov 16, 2026
Start date
Dec 2026 (estimated)
Primary completion
Jan 2028 (estimated)
Completion
Jul 2028 (estimated)
Last update
Nov 16, 2026

Study contacts

Andrew Nicholson, PhD
Contact
annicholson@atlasinstitute.ca
613-722-6521 ext. 7202

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion